Join
today

Boliven PRO is more than just patent search

  • Build and save lists using the powerful Lists feature
  • Analyze and download your search results
  • Share patent search results with your clients

Patents »

US7955805: Nucleic acids and polypeptides useful for diagnosing complications of pregnancy

Share

Filing Information

Inventor(s) S. Ananth Karumanchi · Vikas P. Sukhatme ·
Assignee(s) Beth Israel Deaconess Medical Center ·
Attorney/Agent(s) Kristina Bieker-Brady · Kimya F. Harris · Clark & Elbing LLP ·
Primary Examiner Jacob Cheu ·
Application Number US11300928
Filing date 12/15/2005
Issue date 06/07/2011
Prior Publication Data
Predicted expiration date 11/04/2028
Patent term adjustment 1055
U.S. Classifications 435/71  · 436/518  ·
International Classifications G01N3353  ·
Kind CodeB2
Related U.S. Application DataCROSS-REFERENCE TO RELATED APPLICATIONS
This application claims the benefit of the filing date of U.S. provisional application No. 60/636,275, filed Dec. 15, 2004, herein incorporated by reference.
29 Claims, 84 Drawings


Abstract

Disclosed herein are methods for diagnosing or treating pregnancy related hypertensive disorders that include the use of a polypeptide or a nucleic acid encoding a polypeptide selected from the following: follistatin related protein, interleukin 8, inhibin A, VEGF-C, angiogenin, beta fertilin, hypothetical protein, leukocyte associated Ig-like receptor secreted protein, erythroid differentiation protein, adipogenesis inhibitory factor, corticotropin releasing factor binding protein, alpha-1 anti-chymotrypsin, insulin-like growth factor binding protein-5, CD33L, cytokine receptor like factor 1, platelet derived endothelial growth factor, lysyl hydroxylase isoform 2, stanniocalcin precursor, secreted frizzled related protein, galectin-3, alpha defensin, ADAM-TS3, cholecystokinin precursor, interferon stimulated T-cell alpha chemoattractant precursor, azurocidin, sperminine oxidase, UDP glycosyltransferase 2 family polypeptide B28, neurotrophic tyrosine kinase receptor 2, neutral endopeptidase, CDC28 protein kinase regulatory subunit 2, beta glucosidase, lanosterol synthase, calcium/calmodulin-dependent serine protein kinase, estrogen receptor-alternatively spliced transcript H, chemokine (CX3C motif) receptor 1, tyrosinase-related protein 1, hydoxy-delta-5-steroid dehyrogenase, dihydropyramidinase-like-4, and cytochrome P450-family 11.

Independent Claims | See all claims (29)

  1. 1. A method of diagnosing a subject as having, or having a predisposition to, pre-eclampsia or eclampsia, said method comprising measuring the level of insulin-like growth factor binding protein-5 in a sample from said subject, wherein said sample is a bodily fluid from said subject, and wherein a significant increase in the level of said insulin-like growth factor binding protein-5 as compared to the level in a normal reference, is a diagnostic indicator of said pre-eclampsia or eclampsia or a predisposition to said pre-eclampsia or eclampsia.
  2. 17. A method of diagnosing a subject as having, or having a predisposition to, pre-eclampsia or eclampsia, said method comprising measuring the level of at least one polypeptide in a sample from said subject, wherein said sample is a tissue sample from said subject and wherein said at least one polypeptide is selected from the group consisting of follistatin like 3 protein (FSTL3), beta fertilin, CD33L, neurotrophic tyrosine kinase receptor 2, and beta glucosidase, and wherein a significant increase in the level of said at least one polypeptide as compared to the level in a normal reference, is a diagnostic indicator of said pre-eclampsia or eclampsia or a predisposition to said pre-eclampsia or eclampsia.

References Cited

U.S. Patent Documents

Document NumberAssigneesInventorsIssue/Pub Date
US5194596 California Biotechnology Inc. Tischer et al. Mar 1993
US5219739 Scios Nova Inc. Tischer et al. Jun 1993
US5238819 The Regents of the University of California Roberts et al. Aug 1993
US5240848 Monsanto Company Keck et al. Aug 1993
US5332671 Genetech, Inc. Ferrara et al. Jul 1994
US5543138 Genetics Institute, Inc. Keith Aug 1996
US5660827 Board of Regents, The University of Texas System Thorpe et al. Aug 1997
US5712395 Yissum Research Development Corp. App et al. Jan 1998
US5763441 Sugen, Inc. App et al. Jun 1998
US5830879 St. Elizabeth's Medical Center of Boston, Inc. Isner Nov 1998
US5928641 Health Research Inc. Seon Jul 1999
US5958715 BRF International Muller Sep 1999
US6100071 Genentech, Inc. Davis-Smyth et al. Aug 2000
US6258787 St. Elizabeths Medical Center of Boston, Inc. Isner Jul 2001
US6361946 Licentia Ltd Alitalo et al. Mar 2002
US6365157 ImClone Systems, Inc. Rockwell et al. Apr 2002
US6376199 The Hospital for Sick Children (HSC) Caniggia et al. Apr 2002
US6399585 Larson et al. Jun 2002
US6410322 HYBRIDON INC Robinson Jun 2002
US6447768 Introgene B.V. Van Zonneveld et al. Sep 2002
US6620590 Isis Innovation Limited Groome et al. Sep 2003
US6660534 Midland Bioproducts Corp. McVicker et al. Dec 2003
US6677300 Scios, Inc. Schreiner et al. Jan 2004
US7191068 Proteogenix, Inc. Rosenfeld et al. Mar 2007
US7323346 The General Hospital Corporation Thadhani et al. Jan 2008
US7344892 Beth Israel Deaconess Medical Center, Inc. Thadhani et al. Mar 2008
US20010055781 Groome et al. Dec 2001
US20030114412 Ward et al. Jun 2003
US20030144298 Curwen et al. Jul 2003
US20030220262 Schreiner et al. Nov 2003
US20040038305 Poston et al. Feb 2004
US20040126828 Karumanchi et al. Jul 2004
US20050025762 Karumanchi et al. Feb 2005
US20050148040 Thadhani et al. Jul 2005
US20050170444 Karumanchi et al. Aug 2005
US20050266409 Wyeth Brown et al. Dec 2005
US20060067937 KARUMANCHI S A Karumanchi et al. Mar 2006
US20060183175 Yale University Buhimschi et al. Aug 2006
US20070104707 Beth Israel Deaconess Medical Center Karumanchi et al. May 2007

Foreign Patent Documents

Document NumberAssigneesInventorsIssue/Pub Date
EP0359274ADEZA BIOMEDICAL CORPORATIONMar 1990
EP1417971SCIOS INC.May 2004
WO199828006Jul 1998
WO200237120KINGS COLLEGE LONDONMay 2002
WO2004008946BETH ISRAEL DEACONESS MEDICAL CENTERJan 2004
WO2005077007BETH ISRAEL DEACONESS MEDICAL CENTERAug 2005
WO2006034507BETH ISRAEL - DEACONESS MEDICAL CENTERMar 2006
WO2006069373YALE UNIVERSITYJun 2006
WO2008030283BETH ISRAEL DEACONESS MEDICAL CENTERMar 2008

Other Publications

Milkiewicz et al. J. Physiology 2006, vol. 577, p. 671-678.*
Schedel et al. Ann Rheum Dis 2004 vol. 63, p. 1205-1211.*
Nishizawa et al. Molecular Human Reproduction 2008, vol. 14, p. 595-602.*
Velzing-Aarts et al. Am J Rep Immu 2002 vol. 48, p. 319-322).*
Baker et al., “Elevated Serum Levels of Vascular Endothelial Growth Factor in Patients with Preeclampsia,” Obstet. Gynecol. 86: 815-821 (1995).
Davis-Smyth et al., “The Second Immunoglobulin-Like Domain of the VEGF Tyrosine Kinase Recpetor Flt-1 Determines Ligand Binding and May Initiate a Signal Transduction Cascade,” EMBO J. 15: 4919-4927 (1996).
Davis-Smyth et al., “Mapping the Charged Residues in the Second Immunoglobulin-Like Domain of the Vascular Endothelial Growth Factor/Placenta Growth Factor Receptor Flt-1 Required for Binding and Structural Stability,” J. Biol. Chem. 273: 3216-3222 (1998).
Dvorak, “Vascular Permeability Factor/Vascular Endothelial Growth Factor: A Critical Cytokine in Tumor Angiogenesis and a Potential Target for Diagnosis and Therapy,” J. Clin. Oncol. 20: 4368-4380 (2002).
Errico et al., “Identification of Placenta Growth Factor Determinants for Binding and Activation of Flt-1 Receptor,” J. Biol. Chem. 279: 43929-43939 (2004).
Ferrara, “Role of Vascular Endothelial Growth Factor in Regulation of Physiological Angiogenesis,” Am. J. Physiol. Cell Physiol. 280: C1358-C1366 (2001).
Florio et al., “Inhibins and Activins in Pregnancy,” Mol. Cell. Endocrinol. 225: 93-100 (2004).
Hsieh, “Maternal Serum Placenta Growth Factor and Vascular Endothelial Growth Factor in Pregnancies Complicated by Preeclampsia (Abstract),” Am. J. Obstet. Gynecol. 184: S70 (2001).
Iyer et al., “The Crystal Structure of Human Placenta Growth Factor-1 (PIGF-1), an Angiogenic Protein, at 2.0 Å Resolution,” J. Biol. Chem. 276: 12153-12161 (2001).
Keyt et al., “Identification of Vascular Endothelial Growth Factor Determinants for Binding KDR and FLT-1 Receptors,” J. Biol. Chem. 271: 5638-5646 (1996).
Krauss et al, “Circulating Endothelial Cell Adhesion Molecules as Diagnostic Markers for the Early Identification of Pregnant Women at Risk for Development of Preeclampsia,” Am. J. Obstet. Gynecol. 177: 443-449 (1997).
Krussel et al., “Expression of mRNA for Vascular Endothelial Growth Factor Transmembraneous Recpetors Flt1 and KDR, and the Soluble Receptor sflt in Cycling Human Endometrium,” Mol. Hum. Reprod. 5: 452-458 (1999).
Li et al., “Recombinant VEGF121 Attenuates Hypertension and Improves Kidney Damage in a Rat Model of Preeclampsia,” Hypertension 092098 (2007).
Lyall et al., “Suppression of Serum Vascular Endothelial Growth Factor Immunoreactivity in Normal Pregnancy and in Pre-Eclampsia,” BJOG 104: 223-228 (1997).
Maynard et al., “Sflt-1, a Circulating VEGF Antagonist, is Up-Regulated in Preeclampsia and Contributes to Endothelial Dysfunction,” J. Am. Soc. Nephrol. 13: SU-FC280 (2002).
Moran et al., “Glomerular Ultrafiltration in Normal and Preeclamptic Pregnancy,” J. Am. Soc. Nephrol. 14: 648-652 (2003).
Muller et al., “The Crystal Structure of Vascular Endothelial Growth Factor (VEGF) Refined to 1.93 Å Resolution: Multiple Copy Flexibility and Receptor Binding,” Structure 5: 1325-1338 (1997).
Muller et al., “Vascular Endothelial Growth Factor: Crystal Structure and Functional Mapping of the Kinase Domain Receptor Binding Site,” Proc. Natl. Acad. Sci. USA 94: 7192-7197 (1997).
Nishizawa et al., “Increased Levels of Pregnancy-Associated Plasma Protein-A2 in the Serum of Pre-Eclamptic Patients,” Mol. Hum. Reprod. 14: 595-602 (2008).
Oswald et al., “Mesanchymal Stem Cells Can Be Differentiated into Endothelial Cells In Vitro,” Stem Cells 22: 377-384 (2004).
Olofsson et al., “Vascular Endothelial Growth Factor B (VEGF-B) Binds to VEGF Receptor-1 and Regulates Plasminogen Activator Activity in Endothelial Cells,” Proc. Natl. Acad. Sci. USA 95: 11709-11714 (1998).
Park et al., “Placenta Growth Factor: Potentiation of Vascular Endothelial Growth Factor Bioactivity, In Vitro and In Vivo, and High Affinity Binding to Flt-1 but not to Flk-1/KDR,” J. Biol. Chem. 269: 25646-25654 (1994).
Park et al., “An Elevated Maternal Plasma, but not Amniotic Fluid, Soluble fms-Like Tyrosine Kinase-1 (sFlt-1) at the Time of Mid-Trimester Genetic Amniocentesis is a Risk Factor for Preeclampsia,” Am. J. Obstet. Gynecol. 193: 984-989 (2005).
Powers et al., “Maternal Serum Soluble fms-like Tyrosine Kinase 1 Concentrations are not Increased in Early Pregnancy and Decrease More Slowly Postpartum in Women Who Develop Preeclampsia,” Am. J. Obstet. Gynecol. 193: 185-191 (2005).
Pryor-Koishi et al., “Overproduction of the Follistatin-Related Gene Protein in the Placenta and Maternal Serum of Women with Pre-Eclampsia,” BJOG 114: 1128-1137 (2007).
Reuvekamp et al., “Selective Deficit of Angiogenic Growth Factors Characterises Pregnancies Complicated by Pre-eclampsia,” BJOG 106: 1019-1022 (1999).
Sawano et al., “Flt-1 but not KDR/Flk-1 Tyrosine Kinase is a Receptor for Placenta Growth Factor, Which is Related to Vascular Endothelial Growth Factor,” Cell Growth Differ. 7: 213-221 (1996).
Schultze-Mosgau et al., “Improved Free Vascular Grat Survival in an Irradiated Surgical SIte Following Topical Application of rVEGF,” Int. J. Radiat. Oncol. Biol. Phys. 57: 803-812 (2003).
Takahashi et al., “Antiangiogenic Therapy of Established Tumors in Human Skin/Severe Combined Immunodeficiency Mouse Chimeras by Anti-Endoglin (CD105) Monoclonal Antibodies, and Synergy between Anti-Endoglin Antibody and Cyclophosphamide,” Cancer Res. 61: 7846-7854 (2001).
Wald et al., “Multiple Marker Second Trimester Serum Screening for Pre-Eclampsia,” J. Med. Screen 8: 65-68 (2001).
Walsh et al., “Computer Modelling of the Receptor-Binding Domains of VEGF and PIGF,” Protein Eng. 10: 389-398 (1997).
Wiesmann et al., “Crystal Structure at 1.7 Å Resolution of VEGF in Complex with Domain 2 of the Flt-1 Receptor,” Cell 91: 695-704 (1997).
European Search Report for EP 0359274, completed on Sep. 13, 1990.
Office Action for U.S. Appl. No. 10/624,809, mailed on Jun. 30, 2006.
International Search Report for PCT/US2003/022892, mailed on Nov. 16, 2005.
Reply to Office Action for U.S. Appl. No. 11/019,559, filed Dec. 5, 2006.
Reply to Office Action for U.S. Appl. No. 10/624,809, filed Dec. 7, 2006.
Reply to Office Action for U.S. Appl. No. 10/771,518, filed Dec. 13, 2006.
Office Action for U.S. Appl. No. 10/771,518, mailed on Mar. 8, 2007.
Office Action for U.S. Appl. No. 11/019,559, mailed Mar. 22, 2007.
International Search Report for PCT/US2005/034483, mailed on Apr. 5, 2007.
Office Action for U.S. Appl. No. 10/624,809, mailed on May 1, 2007.
Reply to Office Action for U.S. Appl. No. 10/771,518, filed Sep. 10, 2007.
Reply to Office Action for U.S. Appl. No. 11/019,559, filed Sep. 24, 2007.
Reply to Office Action for U.S. Appl. No. 10/624,809, filed Oct. 24, 2007.
Office Action for U.S. Appl. No. 11/019,559, mailed on Dec. 13, 2007.
Office Action for U.S. Appl. No. 10/624,809, mailed on Dec. 31, 2007.
Reply to Office Action for U.S. Appl. No. 11/019,559, filed Feb. 4, 2008.
Reply to Office Action for U.S. Appl. No. 10/624,809, filed Feb. 14, 2008.
Written Opinion for Singapore Patent Application No. 0704479-5, mailed on Jun. 27, 2008.
Office Action for U.S. Appl. No. 11/235,577, mailed on Jul. 25, 2008.
Written Opinion for Singapore Patent Application No. 0702085-2, dated Sep. 11, 2008.
Reply to Office Action for U.S. Appl. No. 11/235,577, filed Nov. 25, 2008.
European Search Report for EP 05858653, dated Nov. 27, 2008.
Office Action for U.S. Appl. No. 11/443,920, mailed on Jan. 21, 2009.
Office Action for U.S. Appl. No. 11/235,577, mailed on Feb. 18, 2009.
European Examination Report for EP 05815390, dated Mar. 20, 2009.
Ahmed et al., “Regulation of Placental Vascular Endothelial Growth Factor (VEGF) and Placenta Growth Factor (PIGF) and Soluble Flt-1 by Oxygen- A Review,” Placenta 21:S16-S24 (2000).
Baek et al., “Hypoxia-Induced VEGF Enhances Tumor Survivability Via Suppression of Serum Deprivation-Induced Apoptosis,” Oncogene 19:4621-4631 (2000).
Barleon et al., “Soluble VEGFR-1 Secreted by Endothelial Cells and Monocytes is Present in Human Serum and Plasma From Healthy Donors,” Angiogenesis 4:143-154.
Baumgartner et al., “Constitutive Expression of phVEGF165After Intramuscular Gene Transfer Promotes Collateral Vessel Development in Patients with Critical Limb Ischemia,” Circulation 97:1114-1123 (1998).
Belgore et al., “Measurement of Free and Complexed Soluble Vascular Endothelial Growth Factor Receptor, Flt-1, in Fluid Samples: Development and Application of Two New Immunoassays,” Clin. Sci. 100:567-575 (2001).
Belgore et al., “Plasma Levels of Vascular Endothelial Growth Factor and Its Soluble Receptor (SFlt-1) in Essential Hypertension,” Am. J. Cardiol. 87:805-807 (2001).
Belgore et al., “sFlt-1, a Potential Antagonist for Exogenous VEGF,” Circulation 102:E108-E109 (2000).
Belgore et al., “Successful Therapy Reduces Levels of Vascular Endothelial Growth Factor (VEGF) in Patients with Hypertension and Patients with Hypercholesterolemia,” Atherosclerosis 151:599 (2000).
Belgore et al., “Vascular Endothelial Growth Factor and its Receptor, Flt-1, in Smokers and Non-Smokers,” Br. J. Biomed. Sci. 57: 207-213 (2000).
Blann et al., “Plasma Vascular Endothelial Growth Factor and Its Receptor Flt-1 in Patients with Hyperlipidemia and Atherosclerosis and the Effects of Fluvastatin or Fenofibrate,” Am. J. Cardiol. 87:1160-1163 (2001).
Brockelsby et al., “VEGF Via VEGF Receptor-1 (Flt-1) Mimics Preeclamptic Plasma in Inhibiting Uterine Blood Vessel Relaxation in Pregnancy: Implications in the Pathogenesis of Preeclampsia,” Lab Invest. 79:1101-1111 (1999).
Brown et al., “Vascular Permeability Factor mRNA and Protein Expression in Human Kidney,” Kidney Int. 42: 1457-1461 (1992).
Bouletreau et al., “Hypoxia and VEGF Up-Regulate BMP-2 mRNA and Protein Expression in Microvascular Endothelial Cells: Implications for Fracture Healing,” Plast. Reconstr. Surg. 109:2384-2397 (2002).
Celletti et al., “Effect of Human Recombinant Vascular Endothelial Growth Factor 165 on Progression of Atherosclerotic Plaque,” J. Am. Coll. Cardiol. 37:2126-2130 (2001).
Charnock-Jones et al., “Determination of the Circulating Levels of the Soluble Form of the VEGF-R1 (sFlt-1) in Women at High Risk of Developing Pre-Eclampsia,” J. Soc. Gynecol. Investig. 10:166A Abstract No. 230 (2003).
Charnock-Jones et al., “Identification and Localization of Alternately Spliced mRNAs for Vascular Endothelial Growth Factor in Human Uterus and Estrogen Regulation in Endometrial Carcinoma Cell Lines,” Biol. Reprod. 48:1120-1128 (1993).
Chong et al., “Structure and Expression of a Membrane Component of the Inhibin Receptor System,” Endocrinology 141:2600-2607 (2000).
Clark et al., “A Vascular Endothelila Growth Factor Antagonist is Produced by the Human Placenta and Released into the Maternal Circulation,” Biol. Reprod. 59:1540-1548 (1998).
Cockell et al., “Human Placental Syncytiotrophoblast Microvillous Membranes Impaired Maternal Vascular Endothelial Function,” Br. J. Obstet. Gynaecol. 104:235-240 (1997).
Cohen et al., “Amelioration of Diabetic Nephropathy by Treatment with Monoclonal Antibodies Against Glycated Albumin,” Kidney Int. 45:1673-1679 (1994).
Del Sorbo et al., “The Synthesis of Platelet-Activating Factors Modulates Chemotaxis of Monocytes Induced by HIV-1 Tat,” Eur. J. Immunol. 29:1513-1521 (1999).
Deodato et al., “Recombinant AAV Vector Encoding Human VEGF 165 Enhances Wound Healing,” Gene Ther. 9:777-785 (2002).
Eddahibi et al., “Imbalance Between Platelet Vascular Endothelial Growth Factor and Platelet-Derived Growth Factor in Pulmonary Hypertension,” Am. J. Respir. Crit. Care Med. 162:1493-1499 (2000).
Eremina et al., “Glomerular-Specific Alterations of VEGF-A Expression Lead to Distinct Congenital and Acquired Renal Diseases,” J. Clin. Invest. 111:707-716 (2003).
Evans et al., “Characterization of the Binding of Recombinant Mouse Sperm Fertilin α Subunit to Mouse Eggs: Evidence for Function as a Cell Adhesion Molecule in Sperm-Egg Binding,” Dev. Biol. 187:94-106 (1997).
Ferguson, “Meeting Highlights: Highlights of the 48th Scientific Sessions of the American College of Cardiology,” Circulation 100:570-575 (1999).
Ferrara et al., “The Role of Vascular Endothelial Growth Factor in Angiogenesis,” Acta. Haematol. 106:148-156 (2001).
Freedman et al., “Therapeutic Angiogenesis for Coronary Artery Disease,” Ann. Intern. Med. 136:54-71 (2002).
Gille et al., “Analysis of Biological Effects and Signaling Properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2),” J. Biol. Chem. 276:3222-3230 (2001).
Gordon et al., “Phase I Safety and Pharmacokinetic Study of Recombinant Human Anti-Vascular Endothelial Growth Factor in Patients with Advanced Cancer,” J. Clin. Oncol. 19:843-850 (2001).
Graubert et al., “Vascular Repair After Menstruation Involves Regulation of Vascular Endothelial Growth Factor-Receptor Phosphorylation by sFLT-1,” Am. J. Pathol. 158:1399-1410 (2001).
Hayashi et al., “Changes in Urinary Excretion of Six Biochemical Parameters in Normotensive Pregnancy and Preeclampsia,” Am. J. Kidney Dis. 39:392-400 (2002).
He et al., “Alternative Splicing of Vascular Endothelial Growth Factor (VEGF)-R1 (FLT-1) Pre-mRNA is Important for the Regulation of VEGF Activity,” Mol. Endocrinol. 13:537-545 (1999).
He et al., “Vascular Endothelial Growth Factor Signals Endothelial Cell Production of Nitric Oxide and Prostacyclin Through Flk-1/ KDR Activation of c-Src,” J. Biol. Chem. 274:25130-24135 (1999).
Heeschen et al., “Nicotine Stimulates Angiogenesis and Promotes Tumor Growth and Atherosclerosis,” Nat. Med. 7:833-839 (2001).
Helske et al., “Expression of Vascular Endothelial Growth Factor Receptors 1, 2,and 3 in Placentas From Normal and Complicated Pregnancies,” Mol. Hum. Reprod. 7:205-210 (2001).
Henry et al., “Intracoronary Admimistration of Recombinant Human Vascular Endothelial Growth Factor to Patients with Coronary Artery Disease,” Am. Heart J. 142:872-880 (2001).
Holzgreve et al., “Disturbed Feto-Maternal Cell Traffic in Preeclampsia,” Obstet. Gynecol. 91:669-672 (1998).
Hornig et al., “Release and Complex Formation of Soluble VEGFR-1 from Endothelial Cells and Biological Fluids,” Invest. 80:443-454 (2000).
Hunter et al., “Serum Levels of Vascular Endothelial Growth Factor in Preeclamptic and Normotensive Pregnancy,” Hypertension 36:965-969 (2000).
Ikawa et al., “Calmegin is Required for Fertilin α/β Heterodimerization and Sperm Fertility,” Dev. Biol. 240:254-261 (2001).
Isner et al., “VEGF Gene Transfer for Diabetic Neuropathy,” Hum. Gene Ther. 12:1593-1594 (2001).
Isner et al., “Myocardial Gene Therapy,” Nature 415:234-239 (2002).
Kabbinavar et al., “Phase II, Randomized Trial Comparing Bevacizumab Plus Flurouracil (FU)/Leucovorin (LV) with FU/LV Alone in Patients with Metastatic Colorectal Cancer,” J. Clin. Oncol. 21:60-65 (2003).
Kaku et al., “Effects of Vascular Endothelial Growth Factor on Osteoclast Induction During Tooth Movement in Mice,” J. Dent. Res. 80:1880-1883 (2001).
Kendall et al., “Identification of a Natural Soluble Form of the Vascular Endothelial Growth Factor Receptor, FLT-1, and Its Heterodimerization with KDR,” Biochem. Biophys. Res. Commun. 226:324-328 (1996).
Kendall et al., “Inhibition of Vascular Endothelial Cell Growth Factor Activity by an Endogenously Encoded Soluble Recpetor,” Proc. Natl. Acad. Sci. 90:10705-10709 (1993).
Kincaid-Smith “The Renal Lesion of Preeclampsia Revisted,” Am. J. Kidney Dis. 17:144-148 (1991).
Knebelmann et al., “Transforming Growth Factor α is a Target for the Von Hippel-Lindau Tumor Suppressor,” Cancer Res. 58:226-231 (1998).
Koga et al., “Elevated Serum Soluble Vascular Endothelial Growth Factor Receptor1 (sVEGFR-1) Levels in Women with Preeclampsia,” J. Clin. Endocrinol. Metab. 88:2348-2351 (2003).
Koransky, “VEGF Gene Delivery for Treatment of Ischemic Cardiovascular Disease.” Trends Cardiovasc. Med. 12:108-114 (2002).
Kuo et al., “Comparative Evaluation of the Antitumor Activity of Antiangiogenic Proteins Delivered by Gene Transfer,” Proc. Natl. Acad. Sci. U.S.A. 98:4605-4610 (2001).
Lai et al., “Inhibition of Angiogenesis by Adenovirus-Mediated sFlt-1 Expression in a Rat Model of Corneal Neovascularization,” Hum. Gene Ther. 12:1299-1310 (2001).
Lai et al., “Potential Long-Term Inhibition of Ocular Neovascularisation by Recombinant Adeno-Associated Virus-Mediated Secretion Gene Therapy,” Gene Ther. 9:804-813 (2002).
Lain et al., “Contemporary Concepts of the Pathogenesis and Management of Preeclampsia,” JAMA 287:3183-3186 (2002).
LeCouter et al., “Identification of an Angiogenic Mitogen Selective for Endocrine Gland Endothelium,” Nature 412:877-884 (2001).
Leong et al., “Adapting Pharmacokinetic Properties of a Humanized Anti-interleukin-8 Antibody For Therapeutic Applications Using Site-specific Pegylation,” Cytokine 16:106-119 (2001).
Levine et al., “Circulating Angiogenic Factors and the Risk of Preeclampsia,” N. Engl. J. Med. 350:672-683 (2004).
Levine et al., “Trial of Calcium for Preeclampsia Prevention (CPEP): Rationale, Design, and Methods,” Control Clin. Trials 17:442-469 (1996).
Levine et al., “Trial of Calcium to Prevent Preeclampsia,” N. Engl. J. Med. 337:69-76 (1997).
Levine et al., “Two-Stage Elevation of Cell-Free Fetal DNA in Maternal Sera Before Onset of Preeclampsia,” Am. J. Obstet. Gynecol. 190:707-713 (2004).
Levine et al., “Urinary Placental Growth Factor and Risk of Preeclampsia,” JAMA 293:77-85 (2005).
Lip et al., “Plasma VEGF and Soluble VEGF Receptor FLT-1 in Proliferative Retinopathy: Relationship to Endothelial Dysfunction and Laser Treatment,” Invest. Ophthalmol. Vis. Sci. 41:2115-2119 (2000).
Livingston et al., “Placenta Growth Factor is not an Early Marker for the Development of Severe Preeclampsia,” Am. J. Obstet. Gynecol. 184:1218-1220 (2001).
Livingston et al., “Reductions of Vascular Endothelial Growth Factor and Placental Growth Factor Concentrations in Severe Preeclampsia,” Am. J. Obstet. Gynecol. 183:1554-1557 (2000).
Luttun et al., “Soluble VEGF Receptor Flt1: The Elusive Preclampsia Factor Discovered?” J. Clin. Invest. 111: 600-602 (2003).
Margolin et al., “Phase Ib Trial of Intravenous Recombinant Humanized Monoclonal Antibody to Vascular Endothelial Growth Factor in Combination with Chemotherapy in Patients with Advanced Cancer: Pharmacologic and Long-Term Safety Data,” J. Clin. Oncol. 19:851-856 (2001).
Masuda et al., “Vascular Endothelial Growth Factor Enhances Glomerular Capillary Repair and Accelerates Resolution of Experimentally Induced Glomerulonephritis,” Am. J. Pathol. 159:599-608 (2001).
Maynard et al., “Excess Placental Soluble fms-Like Tyrosine Kinase 1 (sFlt1) May Contribute to Endothelial Dysfunction, Hypertension, and Proteinuria in Preeclampsia,” J. Clinical Invest. 111:649-658 (2003).
Mian et al., “Fully Human Anti-Interleukin 8 Antibody Inhibits Tumor Growth in Orthotopic Bladder Cancer Xenografts Via Down-Regulation of Matrix Metalloproteases and Nuclear Factor-κB,” Clin. Cancer Res. 9:3167-3175 (2003).
Mills et al., “Prostacyclin and Thromboxane Changes Predating Clinical Onset of Preeclampsia,” JAMA 281: 356-362 (1999).
Morbidelli et al., “Nitric Oxide Mediates Mitogenic Effect of VEGF on Coronary Venular Endothelium,” Am. J. Physiol. 270:H411-H415 (1996).
Mortensen et al., “Smoking, Sex of the Offspring, and Risk of Placental Abruption, Placenta Previa, and Preeclampsia : A Population-Based Cohort Study,” Acta. Obstet. Gynecol. Scand. 80:894-898 (2001).
Myers et al., “Hypertensive Diseases and Eclampsia,”Curr. Opin. Obstet. Gynecol. 14:119-125 (2002).
Neufeld et al., “Similarities and Differences Between the Vascular Endothelial Growth Factor (VEGF) Splice Variants,” Cancer Metastasis Rev. 15:153-158 (1996).
Newman et al., “Cigarette Smoking and Pre-Eclampsia : Their Association and Effects on Clinical Outcomes,” J. Matern. Fetal Med. 10:166-170. (2001).
Nishimoto et al., “Glomerular Hypertrophy in Preeclamptic Patients with Focal Segmental Glomerulosclerosis: A Morphometric Analysis,” Clin. Nephrol. 51:209-219 (1999).
Ong et al., “First-Trimester Maternal Serum Levels of Placenta Growth Factor as Predictor of Preeclampsia and Fetal Growth Restriction,” Obstet. Gynecol. 98:608-611 (2001).
Ostendorf et al., “VEGF 165Mediates Glomerular Endothelial Repair,” J. Clin. Invest. 104:913-923 (1999).
Page et al., “Excessive Placental Secretion of Neurokinin B During the Third Trimester Causes Pre-Eclampsia,” Nature 405:797-800 (2000).
Parry et al., “Dinucleotide Repeat Polymorphisms within the Flt-1 Gene in Minimal Change Nephropathy,” Eur. J. Immunogenet. 26:321-323 (1999).
Paternoster et al., “Markers of Tubular Damage in Pre-Eclampsia,” Minerva Ginecol. 51:373-377 (1999).
Polliotti et al., “Second-Trimester Maternal Serum Placental Growth Factor and Vascular Endothelial Growth Factor for Predicting Severe, Early-Onset Preeclampsia,” Obstet. Gynecol. 101:1266-1274 (2003).
Quirici et al., “Differentiation and Expansion of Endothelial Cells from Human Bone Marrow CD 133+ Cells, ” Br. J. Haematol. 115:186-194 (2001).
Regnault et al., “Placental Expression of VEGF, PIGF and their Receptors in a Model of Placental Insufficiency-Intrauterine Growth Restriction (PI-IUGR),” Placenta 23:132-144 (2002).
Reimer et al., “Microarray Analysis of Differentially Epxressed Genes in Placental Tissue of Pre-eclampsia: Up-regulation of Obesity-related Genes,” Mol. Hum. Reprod. 8:674-680 (2002).
Rishi et al., “Use of Monoclonal Antibody Against Human Inhibin as a Marker For Sex Cord-stromal Tumors of the Ovary,” Am. J. Surg. Pathol. 21:583-589 (1997).
Roberts, “Endothelial Dysfunction in Preeclampsia,” Semin Reprod. Endocrinol. 16:5-15 (1998).
Roberts et al., “Pathogenesis and Genetics of Pre-Eclampsia,” Lancet. 357:53-56 (2001).
Roes et al., “High Levels of Urinary Vascular Endothelial Growth Factor in Women with Severe Preclampsia,” Int. J. Biol. Markers 19:72-75 (2004).
Sato et al., “Increased Pulmonary Vascular Contraction to Serotonin after Cardiopulmonary Bypass: Role of Cyclooxygenase,” J. Surg. Res. 90:138-143 (2000).
Sibai, “Diagnosis and Management of Gestational Hypertension and Preeclampsia,” Obstet. Gynecol. 102:181-192 (2003).
Sibai et al., “What We Have Learned About Preeclampsia,” Semin. Perinatol. 27:239-246 (2003).
Simon et al., “Expression of Vascular Endothelial Growth Factor and its Receptors in Human Renal Ontogenesis and in Adult Kidney,” Am. J. Physiol. 268:F240-F250 (1995).
Sood et al., “Gene Expression Patterns in Human Placenta,” Proc. Natl. Acad. Sci. USA 103:5478-5483 (2006).
Spencer et al., “First Timester Maternal Serum Placenta Growth Factor (PIGF) Concentrations in Pregnancies with Fetal Trisomy 21 or Trisomy 18,” Prenat. Diagn. 21:718-722 (2001).
Strevens et al., “Glomerular Endotheliosis in Normal Pregnancy and Pre-Eclampsia,” Br. J. Obstet. Gynecol. 110: 831-836 (2003).
Su et al., “Decreased Maternal Serum Placenta Growth Factor in Early Second Trimester and Preeclampsia,” Obstet. Gynecol. 97:898-904 (2001).
Sugimoto et al., “Neutralization of Circulating Vascular Endothelial Growth Factor (VEGF) by Anti-VEGF Antibodies and Soluble VEGF Receptor 1 (sFlt-1) Induces Proteinuria,” J. Biol. Chem. 278:12605-12608 (2003).
Taylor et al., “Longitudinal Serum Concentyrations of Placental Growth Factor: Evidence for Abnormal Placental Angiogenesis in Pathologic Pregnancies,” Am. J. Obstet. Gynecol. 188:177-182 (2003.
Thadhani et al., “First Trimester Placental Growth Factor and Soluble FMS-like Tyrosine Kinase 1 and Risk for Preeclampsia,” J. Clin. Endocrinol. Metab. 89:770-775 (2004).
Tidwell et al., “Low Maternal Serum Levels of Placenta Growth Fctor as an Antecedent of Clinical Preeclampsia,” Am. J. Obstet. Gynecol. 184:1267-1272 (2001).
Tischer et al., “The Human Gene for Vascular Endothelial Growth Factor Multiple Protein Forms are Encoded Through Alternative Exon Splicing,” J. Biol. Chem. 266:11947-11954 (1991).
Tjoa et al., “Plasma Placenta Growth Factor Levels in Midtrimester Pregnancies,” Obstet. Gynecol. 98:600-607 (2001).
Tonner et al., “Hormonal Control of Plasmin and Tissue-type Plasminogen Activator Activity in Rat Milk During Involution of the Mammary Gland,” J. Endocrinol. 167:265-273 (2000).
Tonner et al., “Insulin-like Growth Factor Binding Protein-5 (IGFBP-5) Induces Premature Cell Death in the Mammary Glands of Transgenic Mice,” Development 129:4547-4557 (2000).
Tonner et al., “Insulin-like Growth Factor Binding Protein-5 (IGFBP-5) Potentially Regulates Programmed Cell Death and Plasminogen Activation in the Mammary Gland,” Adv. Exp. Med. Biol. 480:45-53 (2000).
Tortoriello et al., “Human Follistatin-Related Protein: A Structural Homologue of Follistatin with Nuclear Localization,” Endocrinology 142:3426-3434 (2001).
Torry et al., “Expression and Function of Placenta Growth Factor: Implications for Abnormal Placentation,” J. Soc. Gynecol. Investig. 10:178-188 (2003).
Torry et al., “Preeclampsia is Associated with Reduced Serum Levels of Placenta Growth Factor,” Am. J. Obstet. Gynecol. 179:1539-1544 (1998).
Traver et al., “Walking the Walk: Migration and Other Common Themes in Blood and Vascular Development,” Cell 108:731-734 (2002).
Tsatsaris et al., “Overexpression of the Soluble Vascular Endothelial Growth Factor Receptor in Preeclamptic Patients: Pathophysiological Consequences,” J. Clin. Endocrinol. Metab. 88:5555-5563 (2003).
Tucci et al., “rhVEGF and Experimental Rat Skin Flaps: Systemic or Local Administration and Morphological Characteristics,” Int. J. Artif. Organs 24:743-751 (2001).
Vale et al., “Activins and Inhibins and Their Signaling,” Ann. N.Y. Acad. Sci. 1038:142-147 (2004).
Vuorela et al., “Amniotic Fluid-Soluble Vascular Endothelial Growth Factor Receptor-1 in Preeclampsia,” Obstet. Gynecol. 95:353-357 (2000).
Walker, “Pre-Eclampsia,” Lancet 356:1260-1265 (2000).
Wankell et al., “The Activin Binding Proteins Follistatin and Follistatin-related Protein are Differentially Regulated In Vitro and During Cutaneous Wound Repair,” J. Endocrin. 171:385-395 (2001).
Yang et al., “A Randomized Trial of Bevacizumab, an Anti-Vascular Endothelial Growth Factor Antibody, for Metastatic Renal Cancer,” N. Engl. J. Med. 349:427-434 (2003).
Yang et al., “sFlt-1 Gene-Transfected Fibroblasts: A Wound-Specific Gene Therapy Inhibits Local Cancer Recurrence,” Cancer Res. 61:7840-7845 (2001).
Zhang et al., “Birth-Weight-for-Gestational-Age-Patterns By Race, Sex, and Parity in the United States Population,” Obstet. Gynecol. 86:200-208 (1995).
Zhou et al., “Preeclampsia is Associated With Failure of Human Cytotrophoblasts to Mimic a Vascular Adhesion Phenotype. One Cause of Defective Endovascular Invasion in This Syndrome?” J. Clin. Invest. 99:2152-2164 (1997).
Zhou et al., “Vascular Endothelial Growth Factor Ligands and Receptors That Regulate Human Cytotrophoblast Survival Are Dysregulated in Severe Preeclampsia and Hemolysis, Elevated Liver Enzymes, and Low Platelets Syndrome,” Am. J. Pathol. 160:1405-1423 (2002).
Foreign Search Report Application No. SG 200500265-4, 2005.
International Search Report Application No. PCT/US03/22892, 2003.
International Search Report Application No. PCT/US2005/003884, 2005.
European Supplementary Search Report for EP 05858653.8, dated Nov. 19, 2008.
* cited by examiner

Referenced By

The current document is not referenced by other documents.

Patent Family

The current document is not in a family.